Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Kyverna Therapeutics, Inc. (KYTX)

Kyverna Therapeutics signs five-year miv-cel supply deal with ElevateBio

Neutral Impact 3 of 5 product/contract Written later

Kyverna Therapeutics and ElevateBio signed a Clinical and Commercial Supply Agreement on July 23, 2026, replacing their prior manufacturing agreement in its entirety. The deal covers clinical and commercial supply of Kyverna's lead candidate, miv-cel, and requires Kyverna to order minimum quantities in certain years and/or after FDA approval. The filing does not disclose dollar values, so shareholders cannot yet gauge the financial scale of the commitment.

Key points

  • Agreement signed July 23, 2026, and replaces the prior agreement with ElevateBio in its entirety.
  • Initial term of five years, with automatic one-year renewals unless terminated under the agreement's terms.
  • Prices and fees are subject to an annual inflation adjustment up to a maximum percentage, tied to the PPI for Pharmaceutical Preparation Manufacturing.
  • Full agreement to be filed with the Form 10-Q for the quarter ending September 30, 2026; certain terms will be confidential.

The filing

CompanyKyverna Therapeutics, Inc. (KYTX)
Form8-K, current report
Filed with the SECJul 27, 2026, 8:00 AM ET
Accession number0001193125-26-316916

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.